References of "LAMPROYE, Anne"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailThrombose portale étendue chez un patient sous anti-vitamine K
LEDOUBLE, Vinciane ULg; BECK, Emmanuel ULg; PETERS, Pierre ULg et al

in Revue Médicale de Liège (2013), (68(7-8)), 382-6

Detailed reference viewed: 13 (3 ULg)
Full Text
Peer Reviewed
See detailLiver transplantation for acute hepatic failure due to chemotherapy-induced HBV reactivation in lymphoma patients.
Noterdaeme, Timothee; Longree, Luc; Bataille, Christian ULg et al

in World journal of gastroenterology : WJG (2011), 17(25), 3069-72

Hepatitis B (HBV) reactivation induced by chemotherapy is problem encountered recently in the management of malignant diseases. Chemotherapy-induced HBV reactivation may ultimately lead to terminal acute ... [more ▼]

Hepatitis B (HBV) reactivation induced by chemotherapy is problem encountered recently in the management of malignant diseases. Chemotherapy-induced HBV reactivation may ultimately lead to terminal acute liver failure. Liver transplantation (LT) currently remains the only definitive treatment option for such cases, but is generally denied to patients suffering from malignancy. Here, the authors describe 2 cases of cancer-free and HBV graft re-infection-free survival after LT performed for terminal liver failure arising from HBV reactivation induced by chemotherapy for advanced stage lymphoma. These 2 cases, and some other reports in the literature, may suggest that patients suffering from hematologic malignancies and terminal liver disease can be considered for LT if the prognosis of their hematologic malignancy is good. [less ▲]

Detailed reference viewed: 21 (2 ULg)
Full Text
Peer Reviewed
See detailDonation after Cardiac Death increases the number of liver grafts for liver transplantation
Ledinh, H.; HANS, Marie-France ULg; MONARD, Josée ULg et al

in Acta Gastro-Enterologica Belgica (2011, March), 74(1), 10

Detailed reference viewed: 20 (1 ULg)
Full Text
Peer Reviewed
See detailEvolution over a 15 year period of the epidemiological profile of 2884 newly diagnosed HCV patients in Belgium.
LOLY, Jean ULg; GERARD, Christiane ULg; VAIRA, Dolorès ULg et al

in Acta Gastro-Enterologica Belgica (2011, March), 74

Detailed reference viewed: 39 (12 ULg)
Full Text
Peer Reviewed
See detailLIVER TRANSPLANTATION FOR ACUTE HEPATIC FAILURE DUE TO CHEMOTHERAPY-INDUCED HEPATITIS B VIRUS REACTIVATION IN LYMPHOMA PATIENTS
Noterdaeme, T.; Longree, L.; Bataille, C. et al

in Transplant International (2011, February), 24(1), 10-10

Detailed reference viewed: 34 (13 ULg)
Full Text
Peer Reviewed
See detailDéfis pour réduire la mortalité liée à l'hépatite C: améliorer l'accessibilité au traitement et l'observance thérapeutique
Delwaide, Jean ULg; Lamproye, Anne ULg; Belaiche, Jacques ULg

in Revue Médicale de Liège (2010), 65(5-6), 354-357

Current therapies with pegylated interferon and ribavirin are effective to eradicate the virus C. Improvements in the treatment are foreseen in the near future with combination of the current treatment ... [more ▼]

Current therapies with pegylated interferon and ribavirin are effective to eradicate the virus C. Improvements in the treatment are foreseen in the near future with combination of the current treatment with antiviral therapies (antiproteases, antipolymerases). Eradication of the virus, when obtained, has a favorable impact on an individual basis. However, to reduce the mortality related to the virus C at a population level, an important point is the accessibility to the therapy. It has been calculated that the impact of better management of hepatitis C to reduce mortality is minimal, due to a poor accessibility to the therapy. To obtain a significant additional reduction of mortality, a better screening, a better access to therapy and a better compliance are crucial. [less ▲]

Detailed reference viewed: 28 (3 ULg)
Full Text
Peer Reviewed
See detailL’étude du mois. Traitement de l’hépatocarcinome au stade palliatif par Sorafenib (Nexavar) :Résultats de l’étude SHARP (Sorafenib Hepatocarcinoma Assessment Randomized Protocol)
Detry, Olivier ULg; Delwaide, Jean ULg; Deroover, Arnaud ULg et al

in Revue Médicale de Liège (2009), 64(3), 168-170

Curative management of early-stage hepatocarcinoma may include partial hepatic resection, liver transplantation or tumoral necrosis using radiofrequency ablation or alcoholisation. Until recently, no ... [more ▼]

Curative management of early-stage hepatocarcinoma may include partial hepatic resection, liver transplantation or tumoral necrosis using radiofrequency ablation or alcoholisation. Until recently, no efficient therapeutic mean was available for advanced hepatocarcinoma. Sorafenib is a multikinase inhibitor that decreases tumoral proliferation and angiogenesis, and increases apoptosis in many cancer models. The results of a phase 3 randomized, multicentric, study, entitled SHARP, have now demonstrated that Sorafenib increases survival in patients with advanced hepatocarcinoma developed in Child A cirrhosis. Mean survival gain was a little less than 3 months, without any radiologic response or improvement in the delay before symptomatic progression of the disease. The monthly cost of Sorafenib is a little more than 5,000 euros. It is now crucial to evaluate the potential role of Sorafenib in adjuvant therapy after liver resection or radiofrequency ablation of hepatocarcinoma. The CHU of Liège is taking part to a randomized, multicentric study evaluating the use of Sorafenib after liver resection or radiofrequency ablation for hepatocarcinoma. Another future evaluation could be the association of Sorafenib with other antitumoral agents. [less ▲]

Detailed reference viewed: 362 (37 ULg)
Full Text
Peer Reviewed
See detailLiver transplant donation after cardiac death : experience at the University of Liège
Detry, Olivier ULg; Seydel, Benoît ULg; Delbouille, Marie-Hélène ULg et al

in Transplantation Proceedings (2009), 41(2), 582-4

Aim: Donation after cardiac death (DCD) has been proposed to partly overcome the organ donor shortage. In liver transplantation, the additional warm ischemia linked to DCD procurement may promote higher ... [more ▼]

Aim: Donation after cardiac death (DCD) has been proposed to partly overcome the organ donor shortage. In liver transplantation, the additional warm ischemia linked to DCD procurement may promote higher rate of primary non-function and ischemic type biliary lesions. In this study we reviewed the results of DCD liver transplantation at the University of Liège. Patients and Methods: From 2003 to 2007, 13 controlled DCD liver transplantations were consecutively performed. The records of all donors and recipients were retrospectively reviewed, particularly evaluating the outcome and the occurrence of biliary complications. Mean follow-up was 25 months. Results: Mean donor age was 51 years and their mean intensive care stay was 5.4 days. Mean time between ventilation arrest and cardiac arrest was 9.3 min. Mean time between cardiac arrest and arterial flush was 7.7 min. No touch period was 2 to 5 min. Mean graft cold ischemia was 295 min and mean suture warm ischemia was 38 min. Postoperatively there was no primary non-function. Mean peak transaminase was 2,546 UI/ml. Patient and graft survival was 100% at one year. Two patients (15%) developed graft main bile duct stenosis and underwent endoscopic management. No patient developed symptomatic intrahepatic bile duct strictures or needed retransplantation in the follow-up. Conclusions: The experience of the transplantation department of the University of Liege confirms that controlled DCD donors may be a valuable source of transplantable liver grafts, in case of short procurement warm ischemia and short transplant cold ischemia. [less ▲]

Detailed reference viewed: 135 (22 ULg)
Full Text
Peer Reviewed
See detailResults of liver transplantation from controlled donation after cardiac death (DCD) donors: a single center experience
Detry, Olivier ULg; Seydel, Benoît ULg; Veys, C. et al

in Acta Gastro-Enterologica Belgica (2009, January), 72(1), 25

Detailed reference viewed: 61 (17 ULg)
Full Text
Peer Reviewed
See detailLe Fibroscan: une nouvelle méthode d’évaluation non invasive de la fibrose hépatique
Lamproye, Anne ULg; Belaiche, Jacques ULg; Delwaide, Jean ULg

in Revue Médicale de Liège (2007), 62 Spec No

The FibroScan is a device allowing a non invasive diagnosis and quantification of liver fibrosis. The procedure is based on transient elastography and allows to record liver stiffness by measuring the ... [more ▼]

The FibroScan is a device allowing a non invasive diagnosis and quantification of liver fibrosis. The procedure is based on transient elastography and allows to record liver stiffness by measuring the velocity of shear wave across liver parenchyma. The elasticity is directly correlated to velocity of the wave. In chronic hepatitis C, there is a good correlation between liver elasticity and stage of fibrosis. The FibroScan has also been studied in other chronic liver diseases, such as hepatitis B, primary biliary cirrhosis, sclerosing cholangitis, auto-immune hepatitis, alcohol, steatosis, hemachromatosis with reproductible results. In a cirrhotic patient, it also allows to assess the severity of cirrhosis and to evaluate the risk of complication. It is a painless procedure, with a good acceptability by the patients. Therefore, the FibroScan can be regularly performed, allowing the follow up of fibrosis evolution over time. [less ▲]

Detailed reference viewed: 68 (3 ULg)
Full Text
Peer Reviewed
See detailActualites en chirurgie et transplantation hepatique
Detry, Olivier ULg; De Roover, Arnaud ULg; Coimbra Marques, Carla ULg et al

in Revue Médicale de Liège (2007), 62(5-6, May-Jun), 310-6

Over the last 20 years, significant improvements in hepatic surgery and transplantation have allowed better results. Better patients selection, new preoperative modalities aiming at modifying the volume ... [more ▼]

Over the last 20 years, significant improvements in hepatic surgery and transplantation have allowed better results. Better patients selection, new preoperative modalities aiming at modifying the volume of the liver or the tumour, new surgical techniques, and better postoperative management are the keys to improved outcome. These progresses are reviewed in this article. In hepatic surgery, the latest surgical improvements are the possibility of laparoscopic hepatic resection and of radiofrequency ablation. Modern neoadjuvant chemotherapy may in some cases allow a reduction of large liver colorectal metastases and render them resectable. Improved radiological techniques allow better planning of the surgical resections, reduction of the risks by calculation of the residual liver mass, and induction of liver hypertrophy by preoperative portal embolisation. In liver transplantation, the most significant changes were the use of living related liver donors and of non-heart beating donors to overcome the cadaveric organ donor shortage. [less ▲]

Detailed reference viewed: 151 (18 ULg)
Full Text
Peer Reviewed
See detailMise au point d'une hyperferritinémie
Delwaide, Jean ULg; Giet, Didier ULg; Lamproye, Anne ULg et al

in Revue Médicale de Liège (2006), 61(5-6), 329-333

Hemochromatosis is the most common genetic disorder in persons of northern European descent, and the majority of cases are caused by a mutation in the gene HFE. Genetic testing for hemochromatosis is ... [more ▼]

Hemochromatosis is the most common genetic disorder in persons of northern European descent, and the majority of cases are caused by a mutation in the gene HFE. Genetic testing for hemochromatosis is therefore indicated in all patients with increases in transferrine saturation and ferritin levels. When this genetic testing does not demonstrate a hemochromatosis, other diseases responsible for elevated ferritin levels have to be ruled out, mainly hemolytic anemia, chronic inflammatory disorders, liver diseases such as hepatitis B or C, alcohol abuse, and non alcoholic fatty liver disease. In demonstrated iron overload with absence of classic causes, second-line genetic testing should be considered. [less ▲]

Detailed reference viewed: 39 (3 ULg)
Peer Reviewed
See detailReflux gastro-oesophagien et asthme
Lamproye, Anne ULg; Louis, Edouard ULg; Louis, Renaud ULg et al

in Revue Médicale de Liège (1999), 54(10), 805-8

Gastro-oesophageal reflux (GER) is more frequent in asthmatic patients than in the community at large. A causative association between the two diseases is suspected. Twenty-four hour ambulatory ... [more ▼]

Gastro-oesophageal reflux (GER) is more frequent in asthmatic patients than in the community at large. A causative association between the two diseases is suspected. Twenty-four hour ambulatory intraoesophageal pH monitoring represents the golden standard for the diagnosis of GER. The medical and/or surgical treatment of reflux in asthmatic patients with GER can improve pulmonary symptoms and to a lesser extent pulmonary function. The selection of the patients who will benefit from a GER treatment is difficult. Some symptoms like intrinsic asthma, nocturnal crises, could predict a good response to GER treatment. [less ▲]

Detailed reference viewed: 32 (4 ULg)
Full Text
Peer Reviewed
See detailBronchial Eosinophilic Infiltration in Crohn's Disease in the Absence of Pulmonary Disease
Louis, Edouard ULg; Louis, Renaud ULg; Shute, J. et al

in Clinical & Experimental Allergy : Journal of the British Society for Allergy & Clinical Immunology (1999), 29(5), 660-6

BACKGROUND: Immunological and functional bronchopulmonary abnormalities may be present in up to two-thirds of patients with Crohn's disease. Having recently described a mild increase in methacholine ... [more ▼]

BACKGROUND: Immunological and functional bronchopulmonary abnormalities may be present in up to two-thirds of patients with Crohn's disease. Having recently described a mild increase in methacholine airways responsiveness in these patients, we investigated whether this physiological abnormality is associated with bronchial inflammation since it has previously been described in asthma. METHODS: Eighteen patients with Crohn's disease and 15 healthy controls matched for age, atopy and smoking habit, were studied. All the subjects underwent a bronchial methacholine challenge (1, 4 and 16 mg/mL) and a sputum induction by inhalation of hypertonic saline (NaCl 4.5%). The sputum samples were analysed for their cellular composition as well as for the levels of several mediators and proteins in the fluid phase, including eosinophil cationic protein (ECP), myeloperoxydase, albumin, alpha2-macroglobulin, interleukin-8 (IL-8), IgA and IL-8/immunoglobulin A complexes. RESULTS: When compared to control subjects, patients with Crohn's disease had significantly higher sputum eosinophil counts (14.5% [0-79.9%] vs 0.2% [0-2.3%]; P < 0. 001) and ECP levels (26.2 microg/L [4-124.2 microg/L] vs 9.8 microg/L [0-94.2 microg/L]; P < 0.05). However, patients with Crohn's disease had no sign of increased plasma exudation as reflected by sputum levels of albumin and alpha2-macroglobulin similar to those seen in control subjects. Furthermore the sputum levels of IL-8, IgA and IL-8/IgA complexes were not significantly different between the two groups. The magnitude of the fall in forced expiratory volume in 1 s after methacholine inhalation was significantly increased in Crohn's disease patients although it did not correlate with the extent of sputum eosinophilia or with the sputum ECP levels. CONCLUSIONS: Crohn's disease patients without any clinical respiratory involvement have airway eosinophilia without local increased plasma exudation. However, bronchial eosinophilia in Crohn's disease per se is not sufficient to induce clinically significant airway hyperresponsiveness, suggesting that other factors than bronchial eosinophilic infiltration are required for the clinical expression of an airway instability. [less ▲]

Detailed reference viewed: 15 (1 ULg)
Peer Reviewed
See detailPrevalence of hepatitis G virus in a haemodialysis unit
Lamproye, Anne ULg; Delwaide, Jean ULg; Vaira, Dolorès ULg et al

in Acta Gastro-Enterologica Belgica (1999), 62(1), 13-15

Background : Recently, a novel blood-borne virus has been identified and named hepatitis G virus. Transfusion is the main route of transmission. It is known that patients on maintenance dialysis are more ... [more ▼]

Background : Recently, a novel blood-borne virus has been identified and named hepatitis G virus. Transfusion is the main route of transmission. It is known that patients on maintenance dialysis are more susceptible to infections with parenterally-transmitted viruses than the general population. The aim of the present study was to determine the prevalence of hepatitis G infection in a Belgian dialysis unit. Methods: The entire population of our dialysis unit (82 patients) was tested for the presence of hepatitis G virus (HGV) by reverse transcriptase polymerase chain reaction. History of transfusion or renal transplantation coinfections with hepatitis B and C viruses, and serum aminotransferase levels were also tested. Results: Thirteen patients (16%) were found positive for HGV-RNA. Among these patients, 69.2% were infected by the G virus alone, 15.4% were coinfected with B virus, and 15.4% with C virus. All but one patient had a history of transfusion. Ten of the thirteen infected patients (77%) had normal aminotransferase (< 30 UI/l). Three patients had elevated aminotransferase levels (23%); one was coinfected with B virus, one with C virus, and the last one had a diabetes-induced fatty liver infiltration. No liver biopsies were performed. Conclusions :It is concluded that infection with C virus is common among dialyzed patients. This high rate of infection could be related to previous transfusions, but may as well be due to nosocomial transmission. In our series, at least one patient has been contaminated by another road than transplantation or transfusion. Finally, it does not appear clearly that chronic infection with hepatitis G virus induces Liver disease, as defined by elevated aminotransferase level. [less ▲]

Detailed reference viewed: 105 (9 ULg)
Peer Reviewed
See detailLe syndrome hépato-pulmonaire
Lamproye, Anne ULg; Weber, T.; Delwaide, Jean ULg et al

in Médecine & Chirurgie Digestives (1998)

Detailed reference viewed: 33 (5 ULg)
Full Text
Peer Reviewed
See detailLa néphropathie épidémique a Hantavirus
Weekers, Laurent ULg; Biessaux, Yves ULg; Lamproye, Anne ULg et al

in Revue Médicale de Liège (1997), 52(8), 515-519

L'Entre-Sambre-et-Meuse a été le siège d'une épidémie de néphropathie épidémique à Hantavirus (NE) en 199293. Cinq cas ont été rencontrés au CHU de Liège en moins d'un an. Le virus responsable de cette ... [more ▼]

L'Entre-Sambre-et-Meuse a été le siège d'une épidémie de néphropathie épidémique à Hantavirus (NE) en 199293. Cinq cas ont été rencontrés au CHU de Liège en moins d'un an. Le virus responsable de cette affection appartient à la famille dès Hantavirus dont il existe huit sérotypes aux caractéristiques propres en terme de vecteur (rongeurs), de distribution géographique et de pathogénicité. Les pathologies induites chez l'homme vont de la néphropathie épidémique à Hantavirus - d'évolution le plus souvent bénigne- au syndrome pulmonaire à Hantavirus (SPH) - fréquemment mortel - en passant par la fièvre hémorragique avec syndrome rénal (FHSR) de sévérité intermédiaire. Dans nos contrées, on rencontre le sérotype Puumala dont le vecteur est le campagnol roussâtre. L'homme s'infecte par inhalation de particules contaminées et développe dans un pourcentage non précisé des cas, après une période d'incubation de 1 à 3 semaines, un tableau clinique de néphropathie épidémique à Hantavirus. Celui-ci se caractérise par l'apparition brutale d'une fièvre, de myalgies diffuses, de douleurs abdominales et/ou lombaires et de céphalées. Apparaissent ensuite à des degrés divers: nausées et vomissements, oligurie, myopie aiguë, toux,diathèse hémorragique, diarrhée... Biologiquement, on observe l'association d'une insuffisance rénale aiguë et d'une thrombopénie. L'évolution est spontanément favorable dans les deux à trois semaines. Le diagnostic suggéré par la clinique sera confirmé par la sérologie. La physiopathologie de l'insuffisance rénale et de la thrombopénie fait intervenir des interactions complexes entre l'hôte et le virus. Il n'existe pas de thérapeutique spécifique pour la néphropathie épidémique à Hantavirus. Les formes plus sévères (SPH et FHSR) peuvent bénéficierd'un traitement par Ribavirineen iv. [less ▲]

Detailed reference viewed: 66 (3 ULg)